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Summary 
The gene defective in Huntington's disease encodes 
a protein, huntingtin, with unknown function. Antisera 
generated against three separate regions of huntingtin 
identified a single high molecular weight protein of 
320 kDa on immunoblots of human neuroblastoma 
extracts. The same protein species was detected in 
human and rat cortex synaptosomes and in sucrose 
density gradients of vesicle-enriched fractions, where 
huntingtin immunoreacUvity overlapped with the dis- 
tribution of vesicle membrane proteins (SV2, trans- 
ferrin receptor, and synaptophysin). Immunohisto- 
chemistry in human and rat brain revealed widespread 
cytoplasmic labeling of huntingtin within neurons, par- 
ticularly cell bodies and dendrites, rather than the 
more selective pattern of axon terminal labeling char- 
acteristic of many vesicle-associated proteins. At the 
ultrastructural level, immunoreacUvity in cortical neu- 
rons was detected in the matrix of the cytoplasm and 
around the membranes of the vesicles. The ubiquitous 
cytoplasmic distribution of huntingtin in neurons and 
its association with vesicles suggest that huntingtin 
may have a role in vesicle trafficking. 
Introduction 
Huntington's disease (HD) is an autosomal dominant neu- 
rodegenerative disorder that causes progressive motor 
and cognitive impairments in its victims, ultimately leading 
to death (Wexler et al., 1991; Folstein, 1989). Although 
widespread abnormalities in the HD brain have been re- 
ported, the striatum is the most severely affected struc- 
ture, exhibiting marked atrophy and loss of neurons, par- 
ticularly of medium-sized spiny cells (Bruyn et al., 1973; 
Graveland et al., 1985; Vonsattel et al., 1985). The link 
between the genetic change in HD and processes leading 
to cell death remain elusive, although there is considerable 
evidence that excitotoxic or disrupted metabolic pro- 
cesses may be involved in HD (DiFiglia, 1990; Beal et al., 
1993; Coyle and Puttfarcken, 1993). Recently, the gene 
for HD, IT15 (for interesting transcript 15), was isolated 
(The Huntington's Disease Collaborative Research Group, 
1993) and was predicted to encode a protein, huntingtin, 
of 348 kDa molecular weight. The mutation in HD involves 
an expansion of a trinucleotide (CAG) repeat encoding 
glutamines near the 5' end of the coding sequence. IT15 
bears no homology to other known genes, and thus the 
function of huntingtin is not known. Northern analysis and 
in situ hybridization studies (Li et al., 1993; Strong eta!., 
1993; Landwehrmeyer et al., 1995) show that IT15 mRNA 
is widely expressed in all tissues and is highest in brain, 
testes, and a number of tumor cell lines. In brain, IT15 
mRNA is present principally in neurons. IT15 expression 
does not differ measurably in normal and HD brains, ex- 
cept in the HD striatum in which IT15 mRNA is reduced 
or absent, owing to the loss of neurons. Thus, how the 
genetic mutation causes a selective neuronal degenera- 
tion is not readily explained by changes in transcription, 
implicating alterations of the mutant huntingtin protein 
structure and/or function as a critical factor in the patho- 
genesis in HD. 
Polyglutamine tracts have been identified in a number 
of proteins known to function as transcription factors, and 
it was initially speculated that huntingtin may be involved 
in transcription (Gerber et al., 1994). Consistent with this 
idea, a recent immunohistochemical study using anti- 
peptide antisera directed to the C-terminus of huntingtin 
showed both a cytoplasmic and nuclear localization of the 
protein in neuronal somata (Hoogeveen et al., 1993). How- 
ever, in peripheral organ tissues, huntingtin appeared to 
be localized only to the cytoplasm. To elucidate the intra- 
neuronal subcellular localization of huntingtin in brain, we 
generated polyclonal antisera to different regions of the 
predicted coding sequence of IT15. Our results show that 
huntingtin has a cytoplasmic localization in neuronal cell 
bodies, dendrites, and axons in both human and rat brain; 
also, the protein appears to associate in part with the mem- 
branes of vesicles. 
Results 
Characterization of Anti-Huntingtin Antisera 
To evaluate their specificity, purified antisera directed to 
residues 1-17 (Ab 1), 585-745 (Ab 585), and 2911-3140 
(Ab 2911) of human huntingtin were examined on Western 
blots of Escherichia coil extracts containing recombinant 
proteins expressed from IT15 cDNA clones. All of the anti- 
sera selectively recognized the relevant protein antigen on 
Western blot (Figure 1A) and did not recognize unrelated 
fusion proteins or other proteins present in E. coil extracts. 
Each antibody was evaluated by immunoblotting total 
protein extracts of human neuroblastoma cell line SY5Y. 
This cell line had been previously reported to express high 
levels of IT15 mRNA (Li et al., 1993). To compare the size 
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Figure 1. Characterization of Anti-Huntingtin Antisera 
(A) Western blots of E. coli expressed huntingtin fusion proteins with 
Ab 1, Ab 585, and Ab 2911. Fusion protein (1), which contains the 
N-terminal 1-590 residues of normal human huntingtin, s detected 
by the antipeptide antibody Ab 1 (1 i~g/ml). Abl detects no protein in 
E. coli extract without IT15 insert (Con). Fusion protein (585) containing 
residues 585-745 of huntingtin is detected with Ab 585 (2 p,g/ml) but 
not with Ab 2911 (2 p,g/ml). Fusion protein (2911) containing residues 
2911-3140 is seen by Ab 2911 but not by Ab 585. N umbers to the left 
of the Western blots identify positions of molecular weight standards 
in kDa. 
(B) Immunoblots of human neuroblastoma extracts probed with anti- 
sera directed against three regions f huntingtin. Diagram (above) 
shows the location and number of amino acid residues in huntingtin 
used to generate Ab 1, Ab 585, and Ab 2911. QQQ identifies the 
polyglutamine region. Nitrocellulose strips (below) containing 200 I~
total protein transferred from a wide-lane gel wer  immunoblotted with 
Ab 1 (1 pg/ml; lanes 1-3), Ab 585 (1 p_g/ml; lanes 4-6), and Ab 2911 
(3 p_g/ml; anes 7-8). The immune serum was used alone without com- 
petitor (-) in lanes 1,4: and 7. Detection was blocked in the presence 
of a 5-fold excess concentration of the appropriate antigen (+) in lanes 
2, 5, and 8. Huntingtin immunoreactivity was unaffected in the pres- 
ence of a 5-fold excess concentration of an unrelated peptide or protein 
(asterisk) in lanes 3 and 6 (and also 9, which is not shown). Positions 
of molecular weight standards in kDa are shown on the left. 
(C) Immunoreactive huntingtin in synaptosomes f rat and human cor- 
tex. Western blots of synaptosomes (fraction C) are shown from rat 
of the protein species recognized by each of the immune 
sera, nitrocellulose strips containing protein transferred 
from a wide-lane gel were treated with the preimmune or 
immune sera. Results showed that Ab 1, Ab 585, and Ab 
2911 each recognized a similar size, high molecular 
weight band in neuroblastoma SY5Y extracts (Figure 1B). 
Detection of the huntingtin-like protein was blocked when 
the immune sera were preincubated with the appropriate 
antigen and present when the immune sera were preincu- 
bated with an unrelated peptide or protein antigen (Figure 
1 B). Respective preimmune sera were examined similarly 
(data not shown) and did not detect the high molecular 
weight species. The huntingtin-immunoreactive protein 
migrated slightly faster than immunoreactive MAP lb  (mi. 
grating as an apparent molecular weight 320 kDa) and 
thyroglobulin (apparent molecular weight 330 kDa). 
Antisera directed against all three epitopes of huntingtin 
were used to probe extracts of human and rat cortex on 
Western blots (Figure 1C). All antisera recognized a single 
high molecular weight protein of approximately 320 kDa 
in human cortex synaptosomes (fraction C; see Experi- 
mental Procedures) and in total protein extracts of human 
cortex (data not shown). In rat cortex synaptosomes, Ab l ,  
but not Ab 585 and Ab 2911, detected a similar size protein 
(Figure 1 C). These results provided evidence that hunting- 
tin is synthesized in the rat and human brain as a large 
molecular weight protein, which by epitope mapping, 
spans the protein sequence as predicted by the IT15 
cDNA. Additionally, huntingtin was readily detected in syn- 
aptosomes. 
Subcellular Localization of Huntingtin in Brain: 
Biochemical Studies 
Subcellular differentiation was used to determine whether 
huntingtin was distributed with membranes. Huntingtin im- 
munoreactivity was readily detected in fractions con. 
taining P1, P2, P3, LP1, and LP2 (see Experimental Pro- 
cedures), along with immunoreactive synaptophysin, a 
vesicle membrane protein (Figure 2A). Supernatants ($3 
and LS2) exhibited little or no huntingtin immunoreactivity 
(Figure 2A). These results raised the possibility that hun- 
tingtin was associated with a vesicle compartment. The 
distribution of huntingtin was then compared with vesicle 
and nonvesicle proteins on continuous sucrose density 
gradients. Analysis of sucrose density gradients of the 
vesicle-enriched LP2 fractions showed a nearly identical 
correspondence between the distribution of immunoreac- 
tive huntingtin and immunoreactivity of the vesicle mem- 
brane-associated proteins SV2, synaptophysin, and trans- 
ferrin receptor (Cameron et al., 1991; Volknandt, 1995; 
White et al., 1992). In contrast, the pattern of huntingtin 
immunoreactivity differed from that of the plasma mem- 
brane protein, Na÷/K ÷ ATPase (~ subunit). Huntingtin was 
(left) and human cortex (right) probed with Ab 1 (rat and human) and 
Ab585 and Ab 2911 (human). Human synaptosomes were prepared 
from the same control brain. Molecular weight standards in kDa are 
shown on the left. 
Huntingtin in Brain 
1077 
A 
Huntingtin 
Synaptophysin 
PI P2 P3 $3 LP1 LP2 LS2 
B 
Huntingtin - ~ 320 
Na/K- 
ATPase ~110 
Trf-R - ~ 95 
'~ ~,~j i4 ; !, ; i  ~85 
Svnapto- - ~ .~.~ . . . . . . . . . . . . . . . . .  - ~40 
C 
200- 
97- 
46- 
e 
Figure 2. Huntingtin in Human Brain: Biochemical Analysis 
(A) Immunoblots of subcellular fractionation f human cortex extracts. 
Subcellular fractions (20 ~g/mi) isolated from human cortex w re 
probed with Ab 1 (1 :~g/ml) and then with anti-synaptophysin mono- 
clonal antibody (0.5 p.g/ml). Fractions are marked as P1, P2, P3, $3, 
LP1, LP2, and LS2. 
(B) Distribution of huntingtin immunoreactivity with vesicle- and non- 
vesicle-associated proteins after sucrose density gradient fraction- 
ation. LP2 extracts were applied to sucrose density gradients; equal 
volumes of each fraction were evaluated by Western blot analysis. 
Antisera usedare noted to the left of the figure. Approximate molecular 
weights are denoted on the right margin. The sucrose density gradient 
fractions are marked atthe top, from 0.35 M sucrose (lane 1) to 2.0 M 
sucrose (lane 15). 
(C) Immunoprecipitation and immunoblot analysis of human brain vesi- 
cle fraction with anti-huntingtin antisera. LP2 fractions from human 
cortex were treated with a mixture of Ab 1 and Ab 585 (yes + Abl + 
Ab585), Ab 1 alone (ves+ Abl), and Ab 585 (ves+ Ab585). Controls 
included omission of anti-huntingtin antisera (beads alone) and omis- 
sion of beads (Ab585 alone). Inthis assay, magnetic beads conjugated 
to anti-rabbit antibody (Dynal) were used to isolate components of 
subcellular fractions, with anti-huntingtin antisera recognizing either 
an N-terminal (Ab 1 ) or internal (Ab 585) epitope. The blots were probed 
with either Ab 1 (shown) or Ab 585 (data not shown; identical results). 
A single high molecular weight band appears under all three immuno- 
precipitation conditions (arrow). Protein is absent in the controls in 
which beads alone orAb 585 alone were used. The blots were reprobed 
with anti-synaptophysin antibody. Detection of sy aptophysin (arrow- 
head) in the immunoprecipitates is shown in the panel below. The 
small arrow indicates the detection of immunoglobulin. 
therefore enriched in compartments containing vesicle- 
associated proteins. Finally, immunoprecipitation of vesi- 
cles in LP2 fractions was also achieved with the huntingtin 
antisera (Figure 2C). Ab 1 recognized the same size pro- 
tein in Western blots of vesicles immunoprecipitated by 
either Ab 1 or Ab 585, or a mixture of Ab 1 and Ab 585. 
These results were also obtained in Western blots probed 
with Ab 585 following vesicle im munoprecipitation with Ab 
1, Ab 585, or a mixture of both (data not shown). The 
anti-huntingtin antisera also immunoprecipitated struc- 
tures containing synaptophysin (Figure 2C). Huntingtin, 
therefore, copurified with synaptophysin, providing further 
support for the association of huntingtin with vesicles. 
Huntingtin Localization in Brain: 
Immunohistochemical Analysis 
Consistent with the recently reported distribution of IT15 
mRNA in rat and human brain (Li et al., 1993; Strong et 
al., 1993; Landwehrmeyer et al., 1995), huntingtin immu- 
noreactivity detected with Ab 1 was found in neurons 
throughout the rat brain. In the cortex (Figures 3a-3e), 
neurons in all cortical layers were stained. Reaction prod- 
uct appeared within the cytoplasm (Figures 3a and 3d) of 
neuronal cell bodies and could also be detected in den- 
drites (Figure 3d) and axons (Figure 3e) traversing the 
neuropil. Preadsorption with peptides 1-17 eliminated the 
staining from cell bodies and neuropil (Figure 3b), whereas 
preadsorption with an unrelated peptide did not reduce the 
staining (Figure 3c). At the ultrastructural level, reaction 
product was present in the matrix of the cytoplasm and 
along the membranes of vesicles. In cell bodies, discrete 
labeling appeared on the membranes and vesicles of the 
Golgi complex (Figure 4a). Small patches of labeling inter- 
mixed with clusters of vesicles were seen in dendrites (Fig- 
ure 4b), unmyelinated axon fibers (Figure 4c), and axon 
terminals(Figure 4d). Within the matrix, immunoreactivity 
appeared on microtubules, often in association with la- 
beled vesicles (Figure 4b). 
The focalization 0f'huntingti n n the human brain with 
Ab 585 produced a widespread labeling of neurons similar 
to that of Ab 1 in rat brain. In the cortex, Ab 585 reacted 
with neurons in all layers (Figure 5a). Reaction product 
appeared in the cytoplasm (Figure 5a) of cell bodies, den- 
drites, and axons; in the neuropil, the apical and basal 
dendrites of pyramidal cells were prominently labeled (Fig- 
ure 5a, arrows). Preadsorption with the pu rifled fusion pro- 
tein 585-745 eliminated most staining from cell bodies 
and within the neuropil (Figure 5b). Neuronal staining in 
other regions included the Purkinje cells and granule cells 
of the cerebellum (Figure 5c) and the medium-sized cells 
of the caudate nucleus (Figure 5d). At the ultrastructural 
level, peroxidase reaction product in human cortical neu- 
rons was dispersed in patches within the matrix of the 
cytoplasm and was concentrated on and around the mem- 
branes of vesicles in cell bodies, proximal and distal den- 
drites (Figure 5g), and myelinated axons and axon termi- 
nals (Figure 5e). Some of the labeled terminals formed 
synaptic contacts (Figure 5f). Reaction product appeared 
on microtubules, particularly in the dendrites. Immunogold 
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Figure 3. Huntingtin Immunohistochemistry 
with Ab 1 in Rat Cortex: Light Microscopy 
(a) Section treated with Ab 1 exhibits immuno- 
reactivity in the cytoplasm of neurons. 
(to) Preadsorption of Ab 1 with 10-fold excess 
concentration of peptide residues 1-17 blocks 
the staining. 
(c) Presence of 10-fold excess concentration of 
unrelated peptide does not block the staining. 
(d) Immunoreactive dendrites (arrows) and ax- 
ons (arrowheads) appear in regions f heavily 
labeled cortical neuropil. 
(e) Immunoreactive fibers (arrows) traverse the 
neuropil. Bar, 40 I~m (a, b, c); 25 p.m (d and e). 
labeling of P2 fractions showed gold particles in presynap- 
tic profiles adjacent to vesicle membranes but not super- 
imposed on the vesicles (Figure 5h). Gold labeling was 
also seen in the cytoplasmic matrix of postsynaptic profiles 
(Figure 5h). In sections in which the anti-huntingtin anti- 
serawas  omitted, gold particles were rarely present. 
The localization of huntingtin using immunohistochemi- 
cal approaches revealed a broad intraneuronal cyto- 
plasmic distribution of huntingtin in dendrites, somata, and 
axons; additionally, immunohistochemistry supported the 
association of huntingtin with vesicles. 
Discussion 
The recent discovery that the gene defective in HD, IT15, 
is widely expressed in brain and in many internal organ 
tissues raised speculation that the encoded protein, hun- 
tingtin, might serve a common housekeeping function in 
a diversity of cells. The lack of homology to other known 
genes, however, left open the search for the normal role 
of huntingtin in cells. Recent immunohistochemical evi- 
dence for both a cytoplasmic and nuclear localization of 
huntingtin in neurons (Hoogeveen et al., 1993) led to the 
suggestion that this protein might function as a transcrip- 
tion factor. Our findings revealed that huntingtin is distrib- 
uted throughout he neuronal cytoplasm and is associated, 
at least in part, with vesicles. The latter conclusion is based 
on the enrichment of huntingtin in brain fractions con- 
taining vesicles, the immunoprecipitation of vesicles by 
anti-huntingtin antisera, and the ultrastructural evidence 
for huntingtin immunoreactivity around vesicles. It is im- 
portant to emphasize that huntingtin immunoreactvity in 
brain did not exhibit a restricted pattern of axon terminal 
labeling characteristic of synaptic vesicle proteins. Thus, 
huntingtin may contribute to protein trafficking or mem- 
brane cycling throughout the neuron. The presence of 
Figure 4. Immunohistochemical Localization 
of Huntingtin with Ab 1 in Rat Cortex: Electron 
Microscopy 
(a) A portion of a pyramidal cell isshown. I mmu- 
noreactivity is present in the cisternae (left 
arrow) and vesicles (ringed arrow) f the Golgi 
complex (gc); n, nucleus. 
Patches of reaction product are shown in a den- 
drite (b), axon fiber (c), and axon terminal (d). 
(b) Longitudinal section through the dendrite 
of a pyramidal cell is shown. Reaction product 
is present on the membranes of vesicles 
(arrow) and the adjacent microtubule (short 
arrow). Unlabeled microtubules and vesicles 
are identified by small arrows and ringed 
arrows, respectively. 
(c) Immunoreactive vesicles (arrow) in transit 
through a section ~f a small caliber axon. 
(d) The immunoreactivity in the axon terminal 
on the right is associated with vesicles (arrow). 
The labeled terminal forms an asymmetric syn- 
apse with a dendritic spine (s) on the right. The 
terminal on the l ft has no immunoreactivity 
and also contacts a spine (s). 
Bars, 0.25 p_m. 
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Figure 5. Immunohistochemical Localization 
of Huntingtin with Ab 585 in Human Brain 
(a) Neuronal cell bodies and dendritic processes 
(arrows) are labeled throughout the cortex. 
(b) Preadsorption with a 10-fold excess concen- 
tration of fusion protein markedly diminishes 
the staining of cells and neuropil. 
(c) In the cerebellum, huntingtin immunoreac- 
tivity is seen in Pu rkinje cell bodies (p) and their 
dendrites in the molecular layer (m) and also 
in the granule cell layer (g). 
(d) Labeled neurons (arrows) appear through- 
out the caudate nucleus. 
(e) An axon terminal arising from a myelinated 
fiber (ax) contains clusters of immunoreactive 
vesicles (arrows). The mitochondria (m) are un- 
labeled. 
(f) An immunoreactive axon terminal makes n 
asymmetric contact with a dendritic spine (s). 
(g) A labeled dendrite shows patches of reac- 
tion product associated with the membranes 
of vesicles (arrows)• 
(h) Immunogold labeling of a synaptosome 
fraction from the human cortex demonstrates 
the presence of gold particles around vesicles 
(arrows) in a presynaptic profile and within the 
matrix of the cytoplasm (small arrows) postsyn- 
aptically. Bars, 40 ~m (a and b); 60 p.m (c); 30 
p.m (d); 0.5 ~m (e and g); 0.25 I~m (f and h). 
huntingtin within the matrix of the cytoplasm may position 
it to interact with cytoskeletal elements and thereby influ- 
ence vesicle movement along microtubule tracks. In any 
event, further studies of huntingtin that elucidate the vesi- 
cle compartments (synaptic, endosomal, transport) with 
which it associates and its interactions with proteins in- 
volved with membrane transport, docking, and fusion (see 
review by Jahn and S~dhof, 1993) would seem especially 
worthwhile. 
Importantly, results in this study showed that the three 
antisera generated to huntingtin epitopes from the pre- 
dicted N-terminal region flanking the polyglutamine site 
(Ab 1 and Ab 585) and the C-terminus (Ab 2911) recog- 
nized the same size protein. Our data indicated that the 
principal protein encoded by the IT15 gene includes the 
polyglutamine region. These same antisera also detect 
the mutant form of huntingtin isolated from synaptosomal 
preparations in HD brains, the mutant protein having a 
larger molecular weight, consistent with the expanded 
CAG repeat (Aronin and DiFiglia, unpublished data). 
Implications for HD 
Proposed defects in protein trafficking have been identi- 
fied in a number of recessive inherited disorders, including 
cystic fibrosis, hereditary emphysema, and familial hyper- 
cholesterolemia (Amara et al., 1992). Many of these de- 
fects appear to occur at the level of the endoplasmic reticu- 
lum, where incorrectly assembled proteins are degraded, 
resulting in a failure or error in intracellular targeting of 
the protein. The association of huntingtin with vesicle 
membranes suggests that this protein may participate in 
the process of protein targeting. Alteration in huntingtin 
protein structure caused by the CAG expansion in HD 
might lead to impaired vesicle function and protein deliv- 
ery. In neurons, especially those of the striatum, the failure 
of huntingtin to participate in the proper transport, re- 
moval, binding, or recycling of vesicles could lead to a 
metabolic stress and/or abnormalities in neurotransmis- 
sion, resulting in cell death. Further analysis should now 
be possible to test this hypothesis. 
Experimental Procedures 
Antisera Production 
A peptide containing residues 1-t7 of huntingtin was synthesized to 
greater than 95% purity on a multiple peptide synthesizer (Symphony, 
Rainin). Amino acid analysis was performed by high pressure liquid 
chromatography toverify the sequence. A tyrosine residue was added 
to the C-terminus of residue 17; coupling to keyhole lira pet hemocyanin 
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was achieved using bis-diazo-tolidine. White New Zealand Rabbits 
(n = 3) were injected with a 1:1 ratio of Freund's complete adjuvant 
for the first injection and incomplete adjuvant for subsequent boosts 
at 4-6 week intervals. Antisera were affinity purified on AffiGel 15 
(BioRad), to which the peptide conjugated to bovine serum albumin 
was coupled. Preimmune and immune sera were run over separate 
columns and eluted with 0.1 M glycine (pH 2.5) into Tris-HCL (pH 
8.0). Protein concentrations were determined at OD280 for the preim- 
mune and the immune sera. For the production of recombinant pro- 
teins, cDNA fragments encoding residues 585-745 and 2911-3140 
were generated by PCR from IT15 phage clones. The fragments were 
purified and cloned in-frame into bacterial expression vector pQE (Qia- 
gen), which encodes six histidines upstream of the polylinker. Cloned 
fragments were verified by restriction digestion and sequencing. Pro- 
tein expression and purification on Ni-bound resin columns were per- 
formed according to the recommendations of the supplier. Purified 
fractions were verified by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and those with greater than 950/o purity were pooled and 
concentrated (Centricon, Amicon). The purified protein was injected 
without a carrier protein into rabbits using the immunization proce- 
dures described above. The immune serum generated using the six 
histidine-tagged huntingtin fusion proteins was purified on a protein 
A column (Ab 585) or by affinity purification against the antigen on 
nitrocellulose strips (Ab 2911). 
Mon0clonal antisera to synaptophysin (Boeringer-Mannheim), poly- 
clonal antisera to SV2 (gift from Dr. Kathleen M. Buckley, Harvard 
Medical School), monoclonal antisera to human transferrin receptor 
(gift from Dr. lan Trowbridge, Salk Institute), and monoclonal antisera 
to Na--IK + ATPase ~ subunit (Affinity Bioreagents) were also employed. 
Preparation of Protein Extracts from Neuroblastoma Cells 
Human neuroblastoma SY5Y cells were harvested from the culture 
dish into phosphate-buffered saline (PBS) and transferred to RIPA 
buffer (150 mM NaCI, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% 
SDS, 50 mM Tris [pH 8.0]) containing freshly added protease inhibitors 
(0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitoI, 1 I~g/ml 
pepstatin, 70 I~g/ml n-tosyl-l-phenylalanine chloromethyl ketone, 0.5 
mg/ml leupeptin) for 30 rain at 4°C. Cells were passed through a sy- 
ringe several times, then centrifuged at 8000 rpm for 5 min at 4°C. 
The supernatant was collected, and the protein concentration deter- 
mined by Bradford assay (BioRad). Aliquots were stored at -20°C. 
Preparation of Synaptosomal Fractions 
Synaptosomal proteins were prepared and separated on a discontinu- 
ous sucrose density gradient, as adapted from Koenig et al. (1974). 
Rats were decapitated and the cortex rapidly removed and placed 
in 0.32 M sucrose (pH 7.5) containing 0.1 mM phenylmethylsulfonyl 
fluoride and 2 p.g/ml pepstatin A. Human cortex (from the Brain Tissue 
Resource Center, McLean Hospital, Belmont, MA and Dr. Tom Smith, 
University of Massachusetts Medical Center, Worcester, MA), which 
had been stored at -70°C, was thawed in 0.32 M sucrose with the 
same protease inhibitors. Synaptosomal fractions at the 0.8-1.0, 1.0- 
1.2 (fraction C), and 1.2-1.4 M sucrose interfaces were collected, 2 v 
water was added, the fractions were spun at 37,000 x g for 20 rain, 
and the pellets were resuspended in 0.32 M sucrose, 1 mM HEPES 
with protease inhibitors. The fractions were aliquoted and stored at 
-70°C until further analysis. 
Preparation of Vesicles, Separation of Vesicles on Continuous 
Sucrose Gradients, and Immunoprecipitation 
Brain cell fractionation was adapted from Brose et al. (1990) to obtain 
fractions P1, P2, P3, $3, LP1, LP2, and LS2. (P1, initial pellet of ho- 
mogenate; P2, crude synaptosomee; P3, high-spin pellet Of P2 eu- 
pernatant; $3, supernatant of P3 spin; LP1, pellet after hypotonic lysis 
of P2; LP2, pellet of LP1 supernatant; LS2, supernatant of LP2 spin.) 
Brain tissue (either h u man or rat) was homogenized in 10 v (ml/g tissue) 
of 0.32 M sucrose buffer containing 0.05 M Tris (pH 6.8) plus protease 
inhibitors as above and separated using differential centrifugations. 
Fractions were stored at -70°C until further analysis. 
The protocol for the sucrose density gradient spanning 0.35-2.0 M 
sucrose in a 10 ml total volume followed the method of Walch-Solimena 
et al. (1993). Samples (0.75 ml) were collected from the top of the 
gradient. Aliquots of sample were taken for refractive index calculation 
for verification of the density gradient and for protein analysis. 
For immunoprecipitation, either Ab 1, Ab 585, or both were added 
to freshly prepared vesicles (LP2). Concentration of purified antisera 
to vesicle was 5 I~g Ab protein to 40 I~g vesicle protein; antisera 585 
was used at 1:500 dilution to 40 p.g vesicle protein. PBS buffer con- 
taining 5% bovine serum albumin was used; total volume of the mixture 
was 500 p.I. The mixture was incubated at room temperature for 2 
hr; then, 20 p.I Dynabeads (Dynal) were added (conjugated to sheep 
anti-rabbit antisera), and the mixture was incubated overnight at 4°C 
and separated using a magnetic tube rack. The beads were washed 
three times with binding buffer. Protein was eluted off the beads with 
0.5% SDS buffer and submitted to protein electrophoresis. Controls 
included omission of beads and omission of anti-huntingtin antisera. 
Protein Separation and Western Blot 
Protein samples (20-30 i~g/lane) were separated by SDS-PAGE, either 
using a 4% to 20% gradient gel or 10% acrylamide gel containing 
0.05% bis-acrylamide. Proteins were transferred onto nitrocellulose; 
all blots were treated with 5% dry milk in Tris-buffered saline plus 
0.1% Tween-20 (TBST) for 1-3 hr at room temperature or overnight 
at 4°C. Filters were incubated in Ab 1 (0.5-2.0 I~g), Ab 2911 (1-3 I~g), 
or Ab 585 (1:4000) overnight at 4°C, washed three times 15 rain each 
in 200 ml TBST, and then treated with anti-rabbit antisera conjugated 
to horseradish peroxidase at 1:10,000 in 5% dry milk in TBST for 1 
hr at room temperature. After washing three times for 15 min each in 
200 ml buffer, filters were processed for enhanced chemiluminescence 
according to the recommendations of the supplier (ECL Kit, Amer- 
sham), and the blots were exposed to Hyper-film (Amersham). Western 
blots with antisera to synaptophysin, SV2, transferrin receptor, and 
Na÷/K * ATPase ~ subunit were carried out with the above buffers at 
antibody concentrations recommended by the suppliers. 
Immunohistochemistry 
Imrnunoperoxidase and imrnunogold labeling were performed in hu- 
man and rat brain tissues as previously described (Aronin and DiFiglia, 
1992; Sappet al., 1995). Human brain tissue from three normal control 
cases was obtained from the Brain Tissue Resource Center at McLean 
Hospital, Belmont, MA. Rats (n = 4) were deeply anesthetized with 
a 1:1 ratio of ketamine to xylazine (5 mg/1 mg per 100 g body weight) 
and perfused through the heart with 300-400 ml of 4% paraformalde- 
hyde in PBS (n = 2 rats) or the same fixative with 0.1% glutaraldehyde 
added (n = 2 rats). Ab 585 was used at a 1:500-1:2000 dilution in 
the human tissue, and Ab 1 was used at 2.5-5 p.g/ml in the rat. Controls 
for the immunohistochemistry consisted of omission of the primary 
antibody and preadsorption of the primary antibody with a 10-fold con- 
centration of antigen. An unrelated peptide or protein was also used 
in the blocking experiments as a control. For immunogold labeling, 
freshly prepared P2 (50 p,g) fractions were fixed in 20/0 paraformalde- 
hyde-lysine-periodate fixative on ice for 15 min. Ab 585 was used at 
a 1:100 dilution, and 6 nM coiloidal gold conjugated to Protein NG 
(Jackson ImmunoResearch Laboratories) was used at a 1:20 dilution 
in PBS/bovine serum albumin for 6-12 hr at 4°C. Following the immu- 
nohistochemistry, the pellet was postfixed in 2% glutaraldehyde con- 
taining 0.1 M cacodylic acid (pH 7.4) for 1 hr on ice. The tissue was 
washed in buffer and then treated serially with 1% osmium, 1% uranyl 
acetate in 70% alcohol, dehydrated in alcohol, and embedded in Epon. 
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